Patents by Inventor Suoming Zhang

Suoming Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140113890
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
    Type: Application
    Filed: December 23, 2013
    Publication date: April 24, 2014
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Dawei Chen, Venkat Gadhachanda, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Atul Agarwal, Ha Young Kim, Shuoming Li, Cuixian Liu, Suoming Zhang, Milind Deshpande
  • Patent number: 8703742
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: April 22, 2014
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Patent number: 8697641
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I and the pharmaceutically salts thereof. The variables are defined herein. Certain compounds of Formula I are useful as antiviral agents. 4-amino-4-oxobutanoyl peptide cyclic analogues as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide cyclic analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide cyclic analogue as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide cyclic analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: April 15, 2014
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Xiangzhu Wang, Godwin Pais, Akihiro Hashimoto, Venkat Gadhachanda, Dawei Chen, Atul Agarwal, Suoming Zhang, Cuixian Liu, Shouming Li, Milind Deshpande
  • Patent number: 8614180
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: December 24, 2013
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Dawei Chen, Venkat Gadhachanda, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Atul Agarwal, Ha Young Kim, Shouming Li, Cuixian Liu, Suoming Zhang, Milind Deshpande
  • Patent number: 8461134
    Abstract: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: June 11, 2013
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Xianfeng Li, Suoming Zhang, Tsutomu Akama, Yanchen Zhang, Yang Liu, Jacob J. Plattner, Michael Richard Kevin Alley, Yasheen Zhou, James A. Nieman
  • Patent number: 8445430
    Abstract: The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: May 21, 2013
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Suoming Zhang, Avinash Phadke, Milind Deshpande, Venkat Gadhachanda
  • Patent number: 8435984
    Abstract: The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R1-R12 in Formula I are described herein. The invention also includes methods for preparing such compounds. The present invention further includes pharmaceutical compositions containing tertiary amine substituted peptides and methods for using such compounds, including methods for using the compounds to treat hepatitis C infection.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: May 7, 2013
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Atul Agarwal, Xiangzhu Wang, Dawei Chen, Suoming Zhang, Avinash Phadke
  • Patent number: 8183263
    Abstract: The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R3 to R7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: May 22, 2012
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Xiangzhu Wang, Suoming Zhang, Venkat Gadhachanda, Cuixian Liu, Jesse Quinn, Shouming Lee, Dawei Chen, Milind Deshpande, Avinash Phadke
  • Publication number: 20120115813
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: September 7, 2011
    Publication date: May 10, 2012
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Publication number: 20120108576
    Abstract: The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections.
    Type: Application
    Filed: November 30, 2011
    Publication date: May 3, 2012
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Suoming Zhang, Avinash Phadke, Cuixian Liu, Xiangzhu Wang, Jesse Quinn, Dawei Chen, Venkat Gadhachanda, Shouming Li, Milind Deshpande
  • Patent number: 8119665
    Abstract: The invention provides packaged pharmaceutical preparations of Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the variables are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: February 21, 2012
    Assignee: Novartis International Pharmaceutical Ltd.
    Inventors: George P. Luke, George D. Maynard, Scott Mitchell, Andrew Thurkauf, Linghong Xie, LuYan Zhang, Suoming Zhang, He Zhao, Bertrand L. Chenard, Yang Gao, Bingsong Han, Xiao Shu He
  • Patent number: 8106209
    Abstract: The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R1 to R7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: January 31, 2012
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Cuixan Liu, Avinash Phadke, Xiangzhu Wang, Suoming Zhang
  • Patent number: 8088806
    Abstract: The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: January 3, 2012
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Suoming Zhang, Avinash Phadke, Cuixian Liu, Xiangzhu Wang, Jesse Quinn, Dawei Chen, Venkat Gadhachanda, Shouming Li, Milind Deshpande
  • Publication number: 20110212918
    Abstract: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: November 11, 2010
    Publication date: September 1, 2011
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Xianfeng Li, Suoming Zhang, Tsutomu Akama, Yanchen Zhang, Yang Liu, Jacob J. Plattner, Michael Richard Kevin Alley, Yasheen Zhou, James A. Nieman
  • Patent number: 8007767
    Abstract: Amino methyl imidazoles of Formula I are provided: wherein R, R1, R2, R3, R4, R5, and R6 are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. Additionally, this invention provides labeled amino methyl imidazoles compounds, which are useful as probes for the localization of C5a receptors.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: August 30, 2011
    Assignee: Novartis International Pharmaceutical Ltd.
    Inventors: Andrew Thurkauf, He Zhao, Suoming Zhang, Yang Gao
  • Publication number: 20110172187
    Abstract: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: November 11, 2010
    Publication date: July 14, 2011
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. HERNANDEZ, Xiangeng Li, Suoming ZHANG, Tsutomu AKAMA, Yanchen ZHANG, Yang LIU, Jacob J. PLATTNER, Michael Richard Kevin ALLEY, Yasheen ZHOU, James A. NIEMAN
  • Publication number: 20110070168
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Application
    Filed: November 29, 2010
    Publication date: March 24, 2011
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Patent number: 7906619
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: March 15, 2011
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Publication number: 20100292219
    Abstract: The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R1-R12 in Formula I are described herein. The invention also includes methods for preparing such compounds. The present invention further includes pharmaceutical compositions containing tertiary amine substituted peptides and methods for using such compounds, including methods for using the compounds to treat hepatitis C infection.
    Type: Application
    Filed: February 26, 2008
    Publication date: November 18, 2010
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Atul Agarwal, Xiangzhu Wang, Dawei Chen, Suoming Zhang, Avinash Phadke
  • Publication number: 20100216725
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
    Type: Application
    Filed: December 10, 2009
    Publication date: August 26, 2010
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Dawei Chen, Venkat Gadhachanda, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Atul Agarwal, Ha Young Kim, Shuoming Li, Cuixian Liu, Suoming Zhang, Milind Deshpande